OBJECTIVE:Specific immunotherapy is the only treatment for the underlying allergic disease in patients with respiratory allergies. The primary objective of this trial was to evaluate the efficacy and safety of two maintenance doses of immunologically enhanced, standardised quality (SQ+) grass subcutaneous immunotherapy (SCIT) [4,000 SQ+ and 15,000 SQ+; AVANZ(®) Phleum pratense (ALK)] compared with placebo. METHODS: This was a randomised, double-blind, placebo-controlled, phase II/III trial. The primary evaluation was based on the combined rhinoconjunctivitis score during the entire grass pollen season. Adult subjects with grass pollen-induced allergic rhinoconjunctivitis interfering with usual activities or sleep despite symptomatic medication use, were enrolled. RESULTS:Four hundred and fifty subjects were randomised to receive either 4,000 SQ+ (n = 150), 15,000 SQ+ (n = 152) or placebo (n = 148). The average grass pollen exposure was 27 grains/m(3)/day. No statistically significant differences between the active groups and the placebo group were found for clinical endpoints (p > 0.05). Highly statistically significant (p < 0.001) increases in IgG4 and IgE-blocking factor were found for both active groups versus placebo. The most frequently reported adverse events were mild-to-moderate local injection-site reactions; events were generally more frequent with 15,000 SQ+ than with 4,000 SQ+ and placebo. The most common adverse events leading to premature discontinuation from the trial were anaphylactic reactions (one subject from the placebo group and five subjects from the 15,000 SQ+ group). CONCLUSIONS: The inconclusive results were most probably influenced by a very low grass pollen season. Other factors such as the extent of the pre-seasonal treatment could potentially have contributed. The tolerability profile was acceptable for further development.
RCT Entities:
OBJECTIVE: Specific immunotherapy is the only treatment for the underlying allergic disease in patients with respiratory allergies. The primary objective of this trial was to evaluate the efficacy and safety of two maintenance doses of immunologically enhanced, standardised quality (SQ+) grass subcutaneous immunotherapy (SCIT) [4,000 SQ+ and 15,000 SQ+; AVANZ(®) Phleum pratense (ALK)] compared with placebo. METHODS: This was a randomised, double-blind, placebo-controlled, phase II/III trial. The primary evaluation was based on the combined rhinoconjunctivitis score during the entire grass pollen season. Adult subjects with grass pollen-induced allergic rhinoconjunctivitis interfering with usual activities or sleep despite symptomatic medication use, were enrolled. RESULTS: Four hundred and fifty subjects were randomised to receive either 4,000 SQ+ (n = 150), 15,000 SQ+ (n = 152) or placebo (n = 148). The average grass pollen exposure was 27 grains/m(3)/day. No statistically significant differences between the active groups and the placebo group were found for clinical endpoints (p > 0.05). Highly statistically significant (p < 0.001) increases in IgG4 and IgE-blocking factor were found for both active groups versus placebo. The most frequently reported adverse events were mild-to-moderate local injection-site reactions; events were generally more frequent with 15,000 SQ+ than with 4,000 SQ+ and placebo. The most common adverse events leading to premature discontinuation from the trial were anaphylactic reactions (one subject from the placebo group and five subjects from the 15,000 SQ+ group). CONCLUSIONS: The inconclusive results were most probably influenced by a very low grass pollen season. Other factors such as the extent of the pre-seasonal treatment could potentially have contributed. The tolerability profile was acceptable for further development.
Authors: Sheila M Amar; Ronald J Harbeck; Michael Sills; Lori J Silveira; Holly O'Brien; Harold S Nelson Journal: J Allergy Clin Immunol Date: 2009-06-11 Impact factor: 10.793
Authors: Ronald Dahl; Alexander Kapp; Giselda Colombo; Jan G R de Monchy; Sabina Rak; Waltraud Emminger; Montserrat Fernández Rivas; Mette Ribel; Stephen R Durham Journal: J Allergy Clin Immunol Date: 2006-08 Impact factor: 10.793
Authors: C Rask; L Lund; G Lund; B Heydenreich; P Wurtzen; I Bellinghausen; J Saloga; K Lund Journal: Clin Exp Allergy Date: 2012-09 Impact factor: 5.018
Authors: Anthony J Frew; Richard J Powell; Christopher J Corrigan; Stephen R Durham Journal: J Allergy Clin Immunol Date: 2006-02 Impact factor: 10.793
Authors: Stephen R Durham; Waltraud Emminger; Alexander Kapp; Jan G R de Monchy; Sabina Rak; Glenis K Scadding; Peter A Wurtzen; Jens S Andersen; Bente Tholstrup; Bente Riis; Ronald Dahl Journal: J Allergy Clin Immunol Date: 2012-01-29 Impact factor: 10.793
Authors: R Mösges; A F Koch; E Raskopf; J Singh; K Shah-Hosseini; A Astvatsatourov; B Hauswald; Y Yarin; F Corazza; L Haazen; S Pirotton; S Allekotte; G Zadoyan; T Legon; S R Durham; M H Shamji Journal: Allergy Date: 2018-02-13 Impact factor: 13.146